Gene Variant Common in Individuals of African Ancestry May Lead to Reduced Metabolism of the Thiopurine Class of Drugs

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine class of drugs. TPMT∗8 is relatively common in individuals of African or African American descent. A novel studyopens in new tab/window in The Journal of Molecular Diagnosticsopens in new tab/window, published by Elsevier, details the researchers' goal to provide pharmacogenomic testing that can be used clinically to predict drug response that is beneficial to all patients, regardless of their ancestral background.

Thiopurines are a class of drugs that can be used to treat a variety of medical conditions including leukemia, inflammatory bowel disease, and autoimmune disorders. TPMT is an enzyme important in metabolizing thiopurine medications that limits the levels of active metabolite, which contributes to toxicity.

First author Rosalie M. Sterner, MD, PhD, Department of Laboratory Medicine and Pathology, Mayo Clinic in Rochester, notes, "Variants in the TPMT gene can result in decreased enzyme activity. Thus, to prevent thiopurine adverse reactions, individuals are tested to see if they have genetic variants prior to initiation of treatment, so dosing can be adjusted according to enzyme activity. Currently, guidelines do not recommend testing for the TPMT∗8 variant, which is a variant common among individuals of African or African American ancestry (2.3% minor allele frequency) as its function has been considered uncertain."

Researchers combined data from two assays: one to measure TPMT activity and the other that performs genotyping. They compared the TPMT activity of individuals who carry one copy of the TPMT∗8 allele (and one normal copy) to individuals who are considered intermediate metabolizers (they have one normal copy of TPMT and one no function copy of TPMT). They found that individuals who carry TPMT∗8 metabolized the chemotherapeutic 6-mercaptopurine to 6-methylmercapture purine slower than normal metabolizers (two normal copies of TPMT), but faster than the intermediate metabolizers.

Co-lead investigator Ann M. Moyer, MD, PhD, Department of Laboratory Medicine and Pathology, Mayo Clinic in Rochester, explains, "This is important because a competing reaction converts 6-mercaptopurine to the active metabolites that are responsible for toxicity, and reduced TPMT activity is associated with thiopurine toxicity. In addition, we found that the TPMT activity differed with respect to three substrates (6-MP, 6-MPR, and 6-TGR)."

Co-lead investigator John L. Black, MD, Department of Laboratory Medicine and Pathology, Mayo Clinic in Rochester, notes, "Genotyping will only detect the alleles that are targeted by a test. Some laboratories, including ours, are moving to sequencing pharmacogenes by next-generation sequencing (NGS), which allows the detection of all alleles. This sometimes yields results that can be useful when the rare allele has a known function. Equally important, this approach is superior in providing service to individuals of all ancestries because alleles, including rare alleles, often cluster within ancestral groups. NGS sequencing reduces the ethnocentric approach driven by the fact that most tests have been designed for only the most commonly studied ancestral groups.”

This study showing that TPMT∗8 is a reduced function allele could result in recognition of reduced function alleles and more accurate and granular phenotype prediction. However, this would require further study to understand the clinical significance (thiopurine dose tolerated) of reduced function alleles, incorporation into clinical dosing guidelines, and inclusion in allele selection recommendations. These findings have the potential to help shape clinical practice.

Dr. Sterner concludes, "The commonly tested TPMT variants result in a protein with no activity, so as a next step, it will be important to determine whether a dose reduction is warranted in individuals with reduced function alleles, alone or in combination with other variants."

Notes for editors

The article is “Genotype and Phenotype Correlation of the TPMT∗8 Allele in Thiopurine Metabolism,” by Rosalie M. Sterner, MD, PhD, Patricia L. Hall, PhD, Dietrich Matern, MD, PhD, John L. Black, MD, and Ann M. Moyer, MD, PhD (https://doi.org/10.1016/j.jmoldx.2024.07.005opens in new tab/window). The article appears in The Journal of Molecular Diagnostics, volume 26, issue 11 (November 2024), published by Elsevier.

The article is openly available for 30 days at https://www.jmdjournal.org/article/S1525-1578(24)00183-1/fulltextopens in new tab/window.

Full text of this article and additional information are also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window. Journalists wishing to interview the study authors should contact Susanne Ferguson, Mayo Clinic in Rochester, at [email protected]opens in new tab/window.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnosticsopens in new tab/window, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. https://www.jmdjournal.org/opens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.